Search Results - Klimevski, Emily

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T‐cell period: Preservation of vaccine‐associated antibodies between 0 and 6months

    Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T‐cell period: Preservation of vaccine‐associated antibodies between 0 and 6months... by Reynolds, Gemma K, Klimevski, Emily, Saunders, Natalie R, Teenakoon, Gayani S, Harrison, Simon J, Dowling, Mark, Anderson, Mary Ann, Thursky, Karin, Slavin, Monica A, Teh, Benjamin W

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T-cell period: Preservation of vaccine-associated antibodies between 0 and 6 months

    Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T-cell period: Preservation of vaccine-associated antibodies between 0 and 6 month... by Reynolds, Gemma K, Klimevski, Emily, Saunders, Natalie R, Teenakoon, Gayani S, Harrison, Simon J, Dowling, Mark, Anderson, Mary Ann, Thursky, Karin, Slavin, Monica A, Teh, Benjamin W

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post–Autologous Stem Cell Transplant Period

    High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post–Autologous Stem Cell Transplant Period by Hall, Victoria G, Saunders, Natalie R, Klimevski, Emily, Tennakoon, Gayani S, Khot, Amit, Harrison, Simon, Worth, Leon J, Yong, Michelle K, Slavin, Monica A, Teh, Benjamin W

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  4. 4
    Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab

    Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab by Hall, Victoria G, Nguyen, Thi H O, Allen, Lilith F, Rowntree, Louise C, Kedzierski, Lukasz, Chua, Brendon Y, Lim, Chhay, Saunders, Natalie R, Klimevski, Emily, Tennakoon, Gayani S, Seymour, John F, Wadhwa, Vikas, Cain, Natalie, Vo, Kim L, Nicholson, Suellen, Karapanagiotidis, Theo, Williamson, Deborah A, Thursky, Karin A, Spelman, Timothy, Yong, Michelle K, Slavin, Monica A, Kedzierska, Katherine, Teh, Benjamin W

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study

    COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study by Hall, Victoria G., Sim, Beatrice Z., Lim, Chhay, Hocking, Christopher, Teo, Teddy, Runnegar, Naomi, Boan, Peter, Heath, Christopher H., Rainey, Natalie, Lyle, Megan, Steer, Christopher, Liu, Eunice, Doig, Cassandra, Drummond, Kate, Charles, Patrick G.P., See, Katharine, Lim, Lyn-Li, Shum, Omar, Bak, Narin, Mclachlan, Sue-Anne, Singh, Kasha P., Laundy, Nicholas, Gallagher, Jenny, Stewart, Marcelle, Saunders, Natalie R., Klimevski, Emily, Demajo, Jessica, Reynolds, Gemma, Thursky, Karin A., Worth, Leon J., Spelman, Timothy, Yong, Michelle K., Slavin, Monica A., Teh, Benjamin W.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: